BCR and diffuse large B-cell lymphoma: Using an untargeted NMR-based metabolomics approach, we monitored the metabolic changes occurring in the three DLBCL cell models (two OxPhos and one BCR/glycolytic, see above Figure 1F) following treatment with metformin, L-asparaginase, and their combination for 24 h.